ST. LOUIS, Sept. 23 /PRNewswire/ -- Mallinckrodt Inc. (NYSE: MKG) today
announced an $11.8 million expansion of the company's Hobart, N.Y., dosage
pharmaceuticals plant. The Hobart facility, formerly Graham Laboratories, is
expected to become the sole manufacturing and distribution base for
Mallinckrodt's worldwide dosage pharmaceuticals business.
"In a constantly changing market, Mallinckrodt must grow to compete," said
Michael J. Collins, president of Mallinckrodt's Pharmaceuticals Group. "By
bringing our entire dosage business to Hobart, we expect to streamline our
operations and eliminate inefficiencies." Currently, the company's St. Louis
plant distributes all dosage pharmaceuticals products. Construction of the
new Hobart facilities will begin in March 2000 and extend over an 18-month
period.
The plan calls for the construction of a 40,000-square-foot dosage
pharmaceuticals distribution center and a 45,000-square-foot packaging plant.
Both of these facilities will be used to support existing products and will
provide a platform for new Mallinckrodt dosage products.
Collins said that the new distribution center and increased packaging
capacity will enable Mallinckrodt to bring greater strategic focus to its
dosage business and to better integrate manufacturing, packaging and
distribution operations.
Based in St. Louis, Mo., Mallinckrodt Inc. is a global manufacturer and
marketer of specialty medical products designed to sustain breathing, diagnose
disease, and relieve pain. The company does business in more than 100
countries, operates Respiratory, Imaging and Pharmaceuticals product groups
and had fiscal 1999 net sales of $2.6 billion. The Mallinckrodt website
address is ( http://www.mallinckrodt.com ).
Contact Media, Barbara Abbett, 314-654-5230 or Communications@mkg.com, or
Investor, Barbara Gould, 314-654-3190 or Invest@mkg.com, both of Mallinckrodt.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
Company News On-Call:
http://www.prnewswire.com/comp/440950.html or fax,
800-758-5804, ext. 440950
CONTACT:
Media, Barbara Abbett, 314-654-5230 or
Communications@mkg.com, or Investor, Barbara Gould, 314-654-3190
or Invest@mkg.com, both of Mallinckrodt
|
